A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study
Thirty evaluable patients with histologically confirmed primary liver cancer (PLC) were treated with neocarzinostatin (NCS). All patients had measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 1, 2, or 3. NCS 2250 units/m2 was given daily for 5 days, repeated a...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1980-01, Vol.4 (1), p.33-36 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 36 |
|---|---|
| container_issue | 1 |
| container_start_page | 33 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 4 |
| creator | Falkson, G Von Hoff, D Klaassen, D Du Plessis, H Van Der Merwe, C F Van Der Merwe, A M Carbone, P P |
| description | Thirty evaluable patients with histologically confirmed primary liver cancer (PLC) were treated with neocarzinostatin (NCS). All patients had measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 1, 2, or 3. NCS 2250 units/m2 was given daily for 5 days, repeated at 28-day intervals. Hemopoietic suppression was the major side effect. In 23 of 30 patients (13 with leukopenia and 19 with thrombocytopenia), this toxic effect was documented. Other toxic effects included nausea, vomiting, allergic-type reaction, and elevation of NPN. Partial response, with a median duration of 12.7 weeks (range 4--37 weeks) was observed in seven patients. In nine patients the response was classified as no change, and in 14 patients there was progressive disease. NCS has some therapeutic activity in patients with PLC. |
| doi_str_mv | 10.1007/BF00255455 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00255455</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>6244904</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-d5928bfdb76bfd73602f1a54b1643b811346ec53ad7442c3ec55080e5ec2248b3</originalsourceid><addsrcrecordid>eNpFkM1LwzAUwIMoc04v3oUcVeh8SV7a7jjLNgfDHdRzSdt0q3RJSTJh--utTPTyPuD3PvgRcstgzACSp-c5AJcSpTwjQ4aCR5CiOCdDEIiRTAAvyZX3nwCATIgBGcQccQI4JMcp7bbKa7pcUh_21YHamhptS-WOjbE-qNAYev_6llEmExHLB9r3O9U2G6NMoFvdqWB3akynhs6UD9oZmlnbaddPfmm6NqVt7eZAF87uO9o1rQ2nS9fkolat1ze_eUQ-5rP37CVarRfLbLqKSo4sRJWc8LSoqyKJ-9i_ALxmSmLBYhRFypjAWJdSqCpB5KXoawkpaKlLzjEtxIg8nvaWznrvdJ13rtkpd8gZ5D_-8n9_PXx3grt9sdPVH_orTHwD0oFpcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Falkson, G ; Von Hoff, D ; Klaassen, D ; Du Plessis, H ; Van Der Merwe, C F ; Van Der Merwe, A M ; Carbone, P P</creator><creatorcontrib>Falkson, G ; Von Hoff, D ; Klaassen, D ; Du Plessis, H ; Van Der Merwe, C F ; Van Der Merwe, A M ; Carbone, P P</creatorcontrib><description>Thirty evaluable patients with histologically confirmed primary liver cancer (PLC) were treated with neocarzinostatin (NCS). All patients had measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 1, 2, or 3. NCS 2250 units/m2 was given daily for 5 days, repeated at 28-day intervals. Hemopoietic suppression was the major side effect. In 23 of 30 patients (13 with leukopenia and 19 with thrombocytopenia), this toxic effect was documented. Other toxic effects included nausea, vomiting, allergic-type reaction, and elevation of NPN. Partial response, with a median duration of 12.7 weeks (range 4--37 weeks) was observed in seven patients. In nine patients the response was classified as no change, and in 14 patients there was progressive disease. NCS has some therapeutic activity in patients with PLC.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00255455</identifier><identifier>PMID: 6244904</identifier><language>eng</language><publisher>Germany</publisher><subject>Adult ; Antibiotics, Antineoplastic - therapeutic use ; Carcinoma, Hepatocellular - drug therapy ; Child, Preschool ; Drug Evaluation ; Female ; Humans ; Leukopenia - chemically induced ; Liver Neoplasms - drug therapy ; Male ; Pilot Projects ; Thrombocytopenia - chemically induced ; Zinostatin - administration & dosage ; Zinostatin - adverse effects ; Zinostatin - therapeutic use</subject><ispartof>Cancer chemotherapy and pharmacology, 1980-01, Vol.4 (1), p.33-36</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6244904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Falkson, G</creatorcontrib><creatorcontrib>Von Hoff, D</creatorcontrib><creatorcontrib>Klaassen, D</creatorcontrib><creatorcontrib>Du Plessis, H</creatorcontrib><creatorcontrib>Van Der Merwe, C F</creatorcontrib><creatorcontrib>Van Der Merwe, A M</creatorcontrib><creatorcontrib>Carbone, P P</creatorcontrib><title>A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Thirty evaluable patients with histologically confirmed primary liver cancer (PLC) were treated with neocarzinostatin (NCS). All patients had measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 1, 2, or 3. NCS 2250 units/m2 was given daily for 5 days, repeated at 28-day intervals. Hemopoietic suppression was the major side effect. In 23 of 30 patients (13 with leukopenia and 19 with thrombocytopenia), this toxic effect was documented. Other toxic effects included nausea, vomiting, allergic-type reaction, and elevation of NPN. Partial response, with a median duration of 12.7 weeks (range 4--37 weeks) was observed in seven patients. In nine patients the response was classified as no change, and in 14 patients there was progressive disease. NCS has some therapeutic activity in patients with PLC.</description><subject>Adult</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Child, Preschool</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Leukopenia - chemically induced</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Male</subject><subject>Pilot Projects</subject><subject>Thrombocytopenia - chemically induced</subject><subject>Zinostatin - administration & dosage</subject><subject>Zinostatin - adverse effects</subject><subject>Zinostatin - therapeutic use</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1980</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1LwzAUwIMoc04v3oUcVeh8SV7a7jjLNgfDHdRzSdt0q3RJSTJh--utTPTyPuD3PvgRcstgzACSp-c5AJcSpTwjQ4aCR5CiOCdDEIiRTAAvyZX3nwCATIgBGcQccQI4JMcp7bbKa7pcUh_21YHamhptS-WOjbE-qNAYev_6llEmExHLB9r3O9U2G6NMoFvdqWB3akynhs6UD9oZmlnbaddPfmm6NqVt7eZAF87uO9o1rQ2nS9fkolat1ze_eUQ-5rP37CVarRfLbLqKSo4sRJWc8LSoqyKJ-9i_ALxmSmLBYhRFypjAWJdSqCpB5KXoawkpaKlLzjEtxIg8nvaWznrvdJ13rtkpd8gZ5D_-8n9_PXx3grt9sdPVH_orTHwD0oFpcA</recordid><startdate>19800101</startdate><enddate>19800101</enddate><creator>Falkson, G</creator><creator>Von Hoff, D</creator><creator>Klaassen, D</creator><creator>Du Plessis, H</creator><creator>Van Der Merwe, C F</creator><creator>Van Der Merwe, A M</creator><creator>Carbone, P P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19800101</creationdate><title>A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study</title><author>Falkson, G ; Von Hoff, D ; Klaassen, D ; Du Plessis, H ; Van Der Merwe, C F ; Van Der Merwe, A M ; Carbone, P P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-d5928bfdb76bfd73602f1a54b1643b811346ec53ad7442c3ec55080e5ec2248b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1980</creationdate><topic>Adult</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Child, Preschool</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Leukopenia - chemically induced</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Male</topic><topic>Pilot Projects</topic><topic>Thrombocytopenia - chemically induced</topic><topic>Zinostatin - administration & dosage</topic><topic>Zinostatin - adverse effects</topic><topic>Zinostatin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Falkson, G</creatorcontrib><creatorcontrib>Von Hoff, D</creatorcontrib><creatorcontrib>Klaassen, D</creatorcontrib><creatorcontrib>Du Plessis, H</creatorcontrib><creatorcontrib>Van Der Merwe, C F</creatorcontrib><creatorcontrib>Van Der Merwe, A M</creatorcontrib><creatorcontrib>Carbone, P P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Falkson, G</au><au>Von Hoff, D</au><au>Klaassen, D</au><au>Du Plessis, H</au><au>Van Der Merwe, C F</au><au>Van Der Merwe, A M</au><au>Carbone, P P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1980-01-01</date><risdate>1980</risdate><volume>4</volume><issue>1</issue><spage>33</spage><epage>36</epage><pages>33-36</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Thirty evaluable patients with histologically confirmed primary liver cancer (PLC) were treated with neocarzinostatin (NCS). All patients had measurable disease and an Eastern Cooperative Oncology Group (ECOG) performance status of 1, 2, or 3. NCS 2250 units/m2 was given daily for 5 days, repeated at 28-day intervals. Hemopoietic suppression was the major side effect. In 23 of 30 patients (13 with leukopenia and 19 with thrombocytopenia), this toxic effect was documented. Other toxic effects included nausea, vomiting, allergic-type reaction, and elevation of NPN. Partial response, with a median duration of 12.7 weeks (range 4--37 weeks) was observed in seven patients. In nine patients the response was classified as no change, and in 14 patients there was progressive disease. NCS has some therapeutic activity in patients with PLC.</abstract><cop>Germany</cop><pmid>6244904</pmid><doi>10.1007/BF00255455</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1980-01, Vol.4 (1), p.33-36 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00255455 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Antibiotics, Antineoplastic - therapeutic use Carcinoma, Hepatocellular - drug therapy Child, Preschool Drug Evaluation Female Humans Leukopenia - chemically induced Liver Neoplasms - drug therapy Male Pilot Projects Thrombocytopenia - chemically induced Zinostatin - administration & dosage Zinostatin - adverse effects Zinostatin - therapeutic use |
| title | A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T06%3A57%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20neocarzinostatin%20(NSC%20157365)%20in%20malignant%20hepatoma.%20An%20Eastern%20Cooperative%20Oncology%20Group%20pilot%20study&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Falkson,%20G&rft.date=1980-01-01&rft.volume=4&rft.issue=1&rft.spage=33&rft.epage=36&rft.pages=33-36&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/BF00255455&rft_dat=%3Cpubmed_cross%3E6244904%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/6244904&rfr_iscdi=true |